Your session is about to expire
← Back to Search
LB-100 + Chemotherapy + Immunotherapy for Small Cell Lung Cancer
Study Summary
This trial is studying the side effects and best dose of LB-100 when given with carboplatin, etoposide, and atezolizumab to treat patients with extensive-stage small cell lung cancer that has not been treated before.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with congenital long QT syndrome.I haven't taken any kidney-damaging drugs in the last week.My lung cancer is confirmed to be extensive-stage small cell type.Your bilirubin levels must be within a certain range to be eligible.I have a history of lung scarring or inflammation but not due to radiation.I haven't taken any heart-risk drugs in the last week.I am a woman not able to have children, not pregnant, and not breastfeeding.I have had a bone marrow or organ transplant in the past.Your heart's electrical activity is too high on multiple EKG tests.I haven't taken strong P-glycoprotein inhibitors in the last 7 days.You are expected to live for at least 12 more weeks.I agree to use contraception or remain abstinent to prevent pregnancy during and for 6 months after the study.Your liver enzyme levels need to be within a certain range, unless you have liver tumors.You must have at least 100 platelets per microliter of blood.My kidney function, measured by creatinine clearance, is good.I had brain metastases but am now symptom-free, off steroids for 1 week, and finished radiation 2 weeks ago.I do not need frequent procedures to remove fluid from my chest or abdomen.I have not had cancer before, except for specific types or those treated over 5 years ago without coming back.I have been diagnosed with non-small cell lung cancer or a mix of non-small and small cell lung cancer.I have not received a live vaccine in the last 28 days.I haven't had any drug treatments for small cell lung cancer.I am currently on antibiotics for an infection.I haven't taken any drugs that affect liver enzymes in the last week.Your absolute neutrophil count is equal to or greater than 1.5 x 10/L.Your hemoglobin level needs to be at least 9 grams per deciliter.I have been diagnosed with hepatitis B or C.I am HIV positive.I do not have serious heart conditions like recent heart attacks or severe heart disease.I haven't taken certain seizure medications in the last 7 days.I haven't taken warfarin in the last 7 days.I have an autoimmune disease but don't need strong medication for it.I am not on high-dose steroids or immunosuppressants, except for specific allowed conditions.I have high calcium levels in my blood that are not under control.I can take care of myself and perform daily activities.You have a tumor that can be measured and evaluated using specific guidelines called RECIST.
- Group 1: Treatment (LB-100, carboplatin, etoposide, atezolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are participants currently being recruited for this clinical trial?
"Affirmative, the clinical trial is currently on the hunt for participants. This medical trial was initially posted on May 28th 2021 and has been kept up to date as of March 9th 2022. The study seeks 21 individuals across 1 site."
What therapeutic benefits have been observed with the application of Protein Phosphatase 2A Inhibitor LB-100?
"Protein Phosphatase 2A Inhibitor LB-100 is a frequently used treatment for recurrent cases. It has also demonstrated effectiveness in addressing advanced directives, gestational trophoblastic disease and the management of certain forms of cervical cancer."
To what extent is the cohort size of this research study?
"Affirmative. Clinicaltrials.gov contains evidence that on May 28th 2021, this trial began looking for participants and the most recent update was made on March 9th 2022. The study requires 21 individuals at a single clinic to complete it's research objectives."
Is LB-100, a Protein Phosphatase 2A Inhibitor, formally sanctioned by the FDA?
"Given the limited evidence pertaining to Protein Phosphatase 2A Inhibitor LB-100's safety and efficacy, this compound was assigned a score of 1."
Has research been conducted into the efficacy of Protein Phosphatase 2A Inhibitor LB-100 in a clinical setting?
"At present, 318 clinical trials for Protein Phosphatase 2A Inhibitor LB-100 are in their third phase with a total of 1175 live studies. Shanghai is the leading city hosting tests related to this medication; however there are 68,053 locations worldwide conducting investigations on its effectiveness and safety."
Share this study with friends
Copy Link
Messenger